Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$13.60
+2.3%
$13.92
$9.22
$17.35
$24.07B0.07210,424 shs257,437 shs
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$23.26
-0.5%
$24.33
$19.50
$34.84
$76.92B0.59243,830 shs191,333 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$16.91
+0.8%
$16.09
$12.99
$18.90
$53.37B-0.072.64 million shs2.88 million shs
UCB SA stock logo
UCBJY
UCB
$146.33
-3.4%
$143.57
$98.24
$168.76
$57.24B0.4628,654 shs32,353 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.00%-0.30%+0.53%-18.80%+38.54%
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
0.00%+0.69%+1.34%-15.91%-4.46%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.00%+5.15%+7.26%-8.13%+7.62%
UCB SA stock logo
UCBJY
UCB
0.00%+3.08%+1.25%-1.68%+57.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$13.60
+2.3%
$13.92
$9.22
$17.35
$24.07B0.07210,424 shs257,437 shs
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$23.26
-0.5%
$24.33
$19.50
$34.84
$76.92B0.59243,830 shs191,333 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$16.91
+0.8%
$16.09
$12.99
$18.90
$53.37B-0.072.64 million shs2.88 million shs
UCB SA stock logo
UCBJY
UCB
$146.33
-3.4%
$143.57
$98.24
$168.76
$57.24B0.4628,654 shs32,353 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.00%-0.30%+0.53%-18.80%+38.54%
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
0.00%+0.69%+1.34%-15.91%-4.46%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.00%+5.15%+7.26%-8.13%+7.62%
UCB SA stock logo
UCBJY
UCB
0.00%+3.08%+1.25%-1.68%+57.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
2.80
Moderate BuyN/AN/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
3.25
BuyN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
2.25
HoldN/AN/A
UCB SA stock logo
UCBJY
UCB
2.40
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ALPMY, CHGCY, UCBJY, and TAK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/29/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
DowngradeHoldStrong Sell
6/23/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
DowngradeHold (C)Hold (C-)
6/23/2026
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
UpgradeHoldStrong-Buy
6/22/2026
UCB SA stock logo
UCBJY
UCB
UpgradeModerate Sell
6/15/2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
UpgradeHoldBuy
6/15/2026
UCB SA stock logo
UCBJY
UCB
DowngradeStrong-BuyHold
6/11/2026
UCB SA stock logo
UCBJY
UCB
DowngradeHoldStrong Sell
5/29/2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
UpgradeHold
5/25/2026
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
DowngradeStrong-BuyHold
5/13/2026
UCB SA stock logo
UCBJY
UCB
DowngradeStrong-BuyHold
4/29/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
Reiterated RatingHold (C)
(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$14.21B1.73$1.84 per share7.39$5.52 per share2.46
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$8.41B9.10$0.94 per share24.65$4.12 per share5.65
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$28.32B1.90$3.13 per share5.40$15.41 per share1.10
UCB SA stock logo
UCBJY
UCB
$8.76B6.32N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$1.94B$1.0712.6610.97N/A13.66%24.19%11.30%7/29/2026 (Estimated)
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$2.91B$0.9025.9718.17N/A34.98%22.90%19.45%7/23/2026 (Estimated)
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-$1.01B$0.3943.3513.86N/A4.31%11.20%5.48%7/30/2026 (Estimated)
UCB SA stock logo
UCBJY
UCB
$1.76BN/AN/A20.321.37N/AN/AN/A7/30/2026 (Estimated)

Latest ALPMY, CHGCY, UCBJY, and TAK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q1 2027
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.1638N/AN/AN/A$7.19 billionN/A
7/30/2026N/A
UCB SA stock logo
UCBJY
UCB
$2.71N/AN/AN/A$4.57 billionN/A
7/29/2026N/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.3189N/AN/AN/A$3.52 billionN/A
4/27/2026Q4 2026
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.1941$0.33+$0.1359$0.15$3.28 billion$3.38 billion
4/24/2026Q1 2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A$0.22N/A$0.22N/A$2.05 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.292.13%N/A27.10%N/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$0.622.67%N/A68.89%N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.482.84%-6.89%123.08%N/A
UCB SA stock logo
UCBJY
UCB
$0.530.36%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.23
1.09
0.84
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A
4.70
3.82
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.59
1.09
0.60
UCB SA stock logo
UCBJY
UCB
0.20
1.38
1.04

Institutional Ownership

CompanyInstitutional Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
0.01%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%
UCB SA stock logo
UCBJY
UCB
N/A

Insider Ownership

CompanyInsider Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.04%
UCB SA stock logo
UCBJY
UCB
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,7541.81 billionN/ANot Optionable
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
7,7783.29 billionN/ANot Optionable
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,0003.18 billion3.18 billionOptionable
UCB SA stock logo
UCBJY
UCB
10,117378.04 millionN/ANot Optionable

Recent News About These Companies

UCB ADR (UCBJY) Ratios
UCB SA (UCBJY) Analyst/Investor Day Transcript
UCB ADR Stock Price History
TD Cowen maintains UCB stock Buy rating, EUR250 target
UCB SA (UCBJY)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astellas Pharma stock logo

Astellas Pharma OTCMKTS:ALPMY

$13.60 +0.30 (+2.26%)
As of 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Chugai Pharmaceutical stock logo

Chugai Pharmaceutical OTCMKTS:CHGCY

$23.26 -0.11 (-0.47%)
As of 03:59 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$16.90 +0.14 (+0.81%)
Closing price 03:59 PM Eastern
Extended Trading
$16.89 -0.02 (-0.12%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

UCB stock logo

UCB OTCMKTS:UCBJY

$146.33 -5.08 (-3.36%)
As of 03:59 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.